Northwest Biotherapeutics Company Profile (NASDAQ:NWBO)

About Northwest Biotherapeutics (NASDAQ:NWBO)

Northwest Biotherapeutics logoNorthwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing immunotherapy products to treat cancer. One of the product lines (DCVax-L) is designed to cover all solid tumor cancers in which the tumors can be surgically removed. Another product line (DCVax-Direct) is designed for all solid tumor cancers. The Company's lead product, DCVax-L, is in an ongoing Phase III trial for diagnosed Glioblastome multiforme (GBM), with over 60 trial sites. Its second product, DCVax-Direct, is being studied in a 60-patient Phase I/II trial for all types of inoperable solid tumors. The 40-patient Phase I stage of the trial has been completed. The Company is working on preparations for Phase II trials of DCVax-Direct. The Company's platform technology, DCVax, uses activated dendritic cells to mobilize a patient's own immune system, including T cells, B cells and antibodies and natural killer cells, among others to attack cancer cells to attack their cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:NWBO
  • CUSIP: N/A
  • Web:
  • Market Cap: $32.1 million
  • Outstanding Shares: 186,061,000
Average Prices:
  • 50 Day Moving Avg: $0.18
  • 200 Day Moving Avg: $0.36
  • 52 Week Range: $0.14 - $0.98
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.11
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: $623,000.00
  • Price / Sales: 51.52
  • Book Value: ($0.17) per share
  • Price / Book: -1.02
  • EBIDTA: ($79,080,000.00)
  • Net Margins: -5,283.14%
  • Return on Assets: -157.12%
  • Current Ratio: 0.04%
  • Quick Ratio: 0.04%
  • Average Volume: 1.40 million shs.
  • Beta: 1.75
  • Short Ratio: 13.54

Frequently Asked Questions for Northwest Biotherapeutics (NASDAQ:NWBO)

What is Northwest Biotherapeutics' stock symbol?

Northwest Biotherapeutics trades on the NASDAQ under the ticker symbol "NWBO."

How were Northwest Biotherapeutics' earnings last quarter?

Northwest Biotherapeutics, Inc (NASDAQ:NWBO) announced its quarterly earnings results on Monday, August, 10th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.32) by $0.22. The firm earned $0.39 million during the quarter, compared to analysts' expectations of $0.20 million. View Northwest Biotherapeutics' Earnings History.

Where is Northwest Biotherapeutics' stock going? Where will Northwest Biotherapeutics' stock price be in 2017?

0 brokerages have issued 12 month price objectives for Northwest Biotherapeutics' stock. Their forecasts range from $0.61 to $0.61. On average, they expect Northwest Biotherapeutics' stock price to reach $0.61 in the next year. View Analyst Ratings for Northwest Biotherapeutics.

Who are some of Northwest Biotherapeutics' key competitors?

How do I buy Northwest Biotherapeutics stock?

Shares of Northwest Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Northwest Biotherapeutics stock cost?

One share of Northwest Biotherapeutics stock can currently be purchased for approximately $0.17.

Analyst Ratings

Consensus Ratings for Northwest Biotherapeutics (NASDAQ:NWBO) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: $0.61 (253.62% upside)

Analysts' Ratings History for Northwest Biotherapeutics (NASDAQ:NWBO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
12/15/2016S&P Equity ResearchLower Price Target$0.73 -> $0.61N/AView Rating Details
(Data available from 5/26/2015 forward)


Earnings History for Northwest Biotherapeutics (NASDAQ:NWBO)
Earnings by Quarter for Northwest Biotherapeutics (NASDAQ:NWBO)
Earnings History by Quarter for Northwest Biotherapeutics (NASDAQ:NWBO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/10/2015Q2 2015($0.32)($0.54)$0.20 million$0.39 millionViewN/AView Earnings Details
8/15/2014Q2 2014($0.29)($0.53)ViewN/AView Earnings Details
5/15/2014Q1 2014($0.33)($0.46)$0.20 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Northwest Biotherapeutics (NASDAQ:NWBO)
Current Year EPS Consensus Estimate: $-1.8500 EPS
Next Year EPS Consensus Estimate: $-1.6000 EPS


Dividend History for Northwest Biotherapeutics (NASDAQ:NWBO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Northwest Biotherapeutics (NASDAQ:NWBO)
No insider trades for this company have been tracked by


Headline Trends for Northwest Biotherapeutics (NASDAQ:NWBO)
Latest Headlines for Northwest Biotherapeutics (NASDAQ:NWBO)
DateHeadline logoNorthwest Biotherapeutics, Inc. :NWBO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017 - May 24 at 10:20 AM logoWoodford Investment Management LLP Buys Gilead Sciences Inc, Bioverativ Inc, Biogen Inc, Sells ... - May 23 at 6:29 PM logoNorthwest Biotherapeutics (NWBO) Receiving Somewhat Positive Media Coverage, Analysis Shows - April 28 at 1:12 PM logoNorthwest Biotherapeutics (NWBO) Earning Positive News Coverage, Report Finds - April 25 at 8:02 PM logoNorthwest Biotherapeutics, Inc. :NWBO-US: Earnings Analysis: Q4, 2016 By the Numbers : April 20, 2017 - April 20 at 7:02 PM logoNorthwest Bio Receives SEC Subpoena and Other Awful Nuggets From New 10-K - April 18 at 10:04 AM logoNorthwest Biotherapeutics (NWBO) Earning Very Favorable News Coverage, AlphaOne Reports - April 17 at 12:34 PM logoNorthwest Bio Executive Pleads Ignorance about Clinical Trial Halt, Stock Collapse - April 7 at 11:37 AM logoNovocure Glioblastoma Drug Offers Survival Benefits - April 3 at 6:17 PM logoBiotech Stocks Under Scanner -- Rexahn Pharma, Northwest Biotherapeutics, Celldex Therapeutics, and Vertex Pharma - March 31 at 9:08 AM logoNorthwest closes $7.5M capital raise - Seeking Alpha - March 24 at 11:52 PM logoNW Bio Has Closed On Its Registered Direct Offering Of $7.5 Million With Institutional Investors - March 23 at 7:28 PM logoNORTHWEST BIOTHERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements an - March 23 at 7:28 PM logoNW BIO Announces Registered Direct Offering Of $7.5 Million - March 17 at 7:06 PM logoNorthwest Biotherapeutics agrees to pay bondholders $11 million, needs cash - March 16 at 7:40 PM logoBRIEF-NW Bio reaches agreement with convertible note holders - March 10 at 8:41 PM logo8:16 am Northwest Biotherapeutics signed a Note Repurchase Agreement with a group of bondholders affiliated with Whitebox Advisors, holder of $11 mln of the co's convertible senior notes - March 10 at 8:41 PM logoNW Bio Reaches Agreement With Convertible Note Holders - March 10 at 9:21 AM logoNORTHWEST BIOTHERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fi - March 7 at 6:47 PM logoBiotech Stocks under Scanner -- ACADIA Pharma, Clovis Oncology, Galena Biopharma, and Northwest Biotherapeutics - February 21 at 5:56 PM logoFDA lifts hold on Northwest Bio’s brain cancer immunotherapy trial - February 9 at 8:01 PM logoNorthwest Bio Spikes on Lifting of Clinical Hold (NWBO) - February 7 at 9:32 PM logoFDA Lifts Hold on Northwest Bio Cancer Drug Trial - February 7 at 4:30 PM logoBRIEF-NW bio announces lifting of clinical hold on DCVax -l phase III trial by FDA - February 6 at 7:01 PM logoNW Bio Announces Lifting of Clinical Hold on DCVax®-L Phase III Trial By FDA; Progression-Free Survival Events Reached; Overall Survival Events Not Yet Reached - February 6 at 7:01 PM logo9:31 am Northwest Biotherapeutics provides a further update about the Co's Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer; announces lifting of clinical hold on DCVax-l phase III trial by FDA - February 6 at 7:01 PM logoFlu Case Grinds Small Biotech to a Halt - January 23 at 7:17 PM logoNORTHWEST BIOTHERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure - January 23 at 9:49 AM logoNW Bio Presenting At Phacilitate Immunotherapy World Conference - January 18 at 7:33 PM



Northwest Biotherapeutics (NWBO) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by Staff